Astellas Pharma Inc. Stock price

Equities

4503

JP3942400007

Pharmaceuticals

Market Closed - Japan Exchange 02:00:00 2024-03-28 am EDT 5-day change 1st Jan Change
1,625 JPY -1.96% Intraday chart for Astellas Pharma Inc. -3.10% -3.62%
Sales 2024 * 1,569B 10.37B Sales 2025 * 1,674B 11.05B Capitalization 3,035B 20.04B
Net income 2024 * 81.96B 541M Net income 2025 * 153B 1.01B EV / Sales 2024 * 2.25 x
Net Debt 2024 * 503B 3.32B Net Debt 2025 * 440B 2.91B EV / Sales 2025 * 2.08 x
P/E ratio 2024 *
35.2 x
P/E ratio 2025 *
19.2 x
Employees 14,484
Yield 2024 *
4.14%
Yield 2025 *
4.4%
Free-Float 98.82%
More Fundamentals * Assessed data
Dynamic Chart
China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for Enfortumab Vedotin with Keytruda (Pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer CI
Astellas Pharma Inc.'s Vyloy?? (zolbetuximab) Approves in Japan for Treatment of Gastric Cancer CI
Astellas Pharma Inc. Receives Positive CHMP Opinion for XTANDI? in Additional Recurrent Early Prostate Cancer Treatment Setting CI
Bayer to seek approval for menopausal relief drug after third trial win RE
CytomX Therapeutics, Inc. Announces Milestone Achievement in Prospective T-Cell Engaging Bispecific Collaboration with Astellas CI
Hewlett Packard Enterprise's HPE Asset Upcycling Services Selected by Astellas Pharma MT
China Approves Sale of Humanwell Healthcare Unit's Prostate Cancer Treatment MT
Astellas Pharma Initiates Phase 3 Clinical Studies of Fezolinetant for VMS Associated with Menopause in Japan CI
Transcript : Astellas Pharma Inc. - Special Call
Astellas Pharma Inc. Announces Japan's Ministry of Health, Labour and Welfare Grants Priority Review for the Company's Supplemental New Drug Application for PADCEV with KEYTRUDA CI
Transcript : Astellas Pharma Inc., Q3 2024 Earnings Call, Feb 05, 2024
Astellas Pharma Inc. Submits Supplemental New Drug Application in Japan for PADCEV with KEYTRUDA for First-Line Treatment of Advanced Bladder Cancer CI
Astellas Pharma Inc. Announces Strategic Collaboration with Mass General Brigham CI
Pfizer Says Application for Bladder Cancer Combination Treatment Validated for Review by European Regulator MT
European Medicines Agency Validates Type II Variation Application for PADCEV®? (enfortumab Vedotin) with KEYTRUDA®? (Pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer CI
More news

Latest transcript on Astellas Pharma Inc.

1 day-1.96%
1 week-3.10%
Current month-1.60%
1 month-2.34%
3 months-3.53%
6 months-22.23%
Current year-3.62%
More quotes
1 week
1 622.00
Extreme 1622
1 696.50
1 month
1 551.00
Extreme 1551
1 696.50
Current year
1 551.00
Extreme 1551
1 801.50
1 year
1 551.00
Extreme 1551
2 360.50
3 years
1 551.00
Extreme 1551
2 360.50
5 years
1 375.00
Extreme 1375
2 360.50
10 years
1 062.00
Extreme 1062
2 360.50
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 86-03-31
Director of Finance/CFO 52 Oct. 31
Chairman 63 86-03-31
Members of the board TitleAgeSince
Director/Board Member 67 21-05-31
Director/Board Member 74 17-05-31
Chief Executive Officer 61 86-03-31
More insiders
Date Price Change Volume
24-03-28 1,625 -1.96% 9 670 000
24-03-27 1,692 +1.07% 12,397,500
24-03-26 1,674 +1.27% 8,019,600
24-03-25 1,654 -1.11% 7,191,500
24-03-22 1,672 -0.30% 10,452,200

Delayed Quote Japan Exchange, March 28, 2024 at 02:00 am EDT

More quotes
Astellas Pharma Inc. specializes in the research, development, manufacturing and marketing of pharmaceutical products. Products are especially for immune diseases, infectious diseases, skin diseases, cancer and urologic disorders. Net sales are distributed geographically as follows: Japan (28.8%), Americas (34.5%) and others (36.7%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
1,692 JPY
Average target price
2,142 JPY
Spread / Average Target
+26.56%
Consensus
  1. Stock
  2. Equities
  3. Stock Astellas Pharma Inc. - Japan Exchange